Registro de pacientes con distrofinopatías en Colombia


Autoria(s): Eslava Otálora, Andrea Cecilia
Contribuinte(s)

Mateus Arbelaez, Heidi Eliana

Data(s)

17/08/2016

Resumo

INTRODUCCIÓN. La distrofia muscular de Duchenne es una enfermedad neuromuscular con una herencia recesiva ligada al X que afecta a 1 de cada 3500 niños nacidos vivos. Se produce por mutaciones en el gen DMD que codifica para la distrofina. Se caracteriza por manifestaciones clínicas variables típicas de una distrofia muscular proximal progresiva. OBJETIVO. Realizar el primer registro en Colombia de los pacientes identificados con distrofinopatías, teniendo en cuenta características clínicas y paraclínicas, así como las mutaciones causales de esta patología. METODOLOGÍA Es un estudio descriptivo, transversal, de la revisión de historias clínicas de los pacientes con diagnóstico de DMD atendidos en la consulta de Genética de la Universidad del Rosario durante los años 2006 a 2015. RESULTADOS Se identificaron 99 pacientes, de los cuales 56 (56,56%) corresponden al fenotipo Duchenne y 12 (12,12%) al Becker. No fue posible clasificar a 31 pacientes (31,3%) por falta de datos clínicos. La edad de inicio de los síntomas fue en promedio de 4,41 años. Las mutaciones más frecuentes fueron las deleciones (69%), seguidas por las mutaciones puntuales(14%), las duplicaciones (11%) y por otras mutaciones (4%). CONCLUSIONES Este registro de distrofinopatías es el primero reportado en Colombia y el punto de partida para conocer la incidencia de la enfermedad, caracterización clínica y molecular de los pacientes, garantizando así el acceso oportuno a los nuevos tratamientos de medicina de precisión que permitan mejorar la calidad de vida de los pacientes y sus familias.

INTRODUCTION. Duchenne muscular dystrophy is a neuromuscular disease with X-linked recessive inheritance that affects 1 in 3,500 live births. It is caused by mutations in the DMD gene coding for dystrophin. It is characterized by typical variable clinical manifestations of progressive proximal muscular dystrophy. OBJECTIVE. Perform the first registry in Colombia of patients identified with dystrophinopathies, taking into account clinical and paraclinical characteristics and causal mutations of this disease. METHODOLOGY It is a transversal, descriptive study of the review of medical records of patients diagnosed with DMD treated at the Genetics unit at the University of Rosario during the years 2006-2015. RESULTS 99 patients were identified, of which 56 (56.56%) correspond to Duchenne phenotype and 12 (12.12%) to Becker. It was not possible to classify 31 patients (31.3%) due to lack of clinical data. The age of onset of symptoms was on average 4.41 years. The most frequent mutations were deletions (69%), followed by point mutations (14%), duplication (11%) and other mutations (4%). CONCLUSIONS This registry of dystrophinopathies is the first reported in Colombia and the starting point to determine the incidence of the disease, clinical and molecular characterization of patients, ensuring timely access to new medical treatments precision to improve the quality of life of patients and their families

Formato

application/pdf

Identificador

http://repository.urosario.edu.co/handle/10336/12351

Idioma(s)

spa

Publicador

Facultad de medicina

Direitos

info:eu-repo/semantics/embargoedAccess

Fonte

instname:Universidad del Rosario

reponame:Repositorio Institucional EdocUR

Aartsma-rus, A., Bremmer-bout, M., Janson, A. A. M., Dunnen, J. T. Den, Ommen, G. B. Van, & Deutekom, J. C. T. Van. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, 12.

Aartsma-Rus, A., Ferlini, A., & Vroom, E. (2014). Biomarkers and surrogate endpoints in Duchenne: Meeting report. Neuromuscular Disorders, 24(8), 743–745. http://doi.org/10.1016/j.nmd.2014.03.006

Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., Van Deutekom, J., Van Ommen, G. J., & Den Dunnen, J. T. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation, 30(3), 293–299. http://doi.org/10.1002/humu.20918

Aartsma-rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic diagnosis for Duchenne muscular dystrophy, 1–7. http://doi.org/10.1136/jmedgenet-2015-103387

Aartsma-Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. J. B., & Den Dunnen, J. T. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle and Nerve, 34(2), 135–144. http://doi.org/10.1002/mus.20586

Abbs, S., Tuffery-Giraud, S., Bakker, E., Ferlini, A., Sejersen, T., & Mueller, C. R. (2010a). Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders : NMD, 20(6), 422–7. http://doi.org/10.1016/j.nmd.2010.04.005

Abbs, S., Tuffery-Giraud, S., Bakker, E., Ferlini, A., Sejersen, T., & Mueller, C. R. (2010b). Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders : NMD, 20(6), 422–7. http://doi.org/10.1016/j.nmd.2010.04.005

Bladen, C. L., Rafferty, K., Straub, V., Monges, S., Moresco, A., Dawkins, H., … Lochmüller, H. (2013). The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Human Mutation, 34(11), 1449–57. http://doi.org/10.1002/humu.22390

Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., … Lochmüller, H. (2015). The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations. Human Mutation, 36(4), 395–402. http://doi.org/10.1002/humu.22758

Borun, P., Kubaszewski, L., Banasiewicz, T., Walkowiak, J., Skrzypczak-Zielinska, M., Kaczmarek-Rys, M., & Plawski, A. (2014). Comparative-high resolution melting: A novel method of simultaneous screening for small mutations and copy number variations. Human Genetics, 133(5), 535–545. http://doi.org/10.1007/s00439-013-1393-1

Brabec, P., Vondráček, P., Klimeš, D., Baumeister, S., Lochmüller, H., Pavlík, T., & Gregor, J. (2009). Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscular Disorders, 19(4), 250–254. http://doi.org/10.1016/j.nmd.2009.01.005

Bradley, D., & Parsons, E. (1998). Newborn screening for Duchenne muscular dystrophy. Seminars in Neonatology, 3(1), 27–34. http://doi.org/10.1016/S1084-2756(98)80146-2

Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology, 9(1), 77–93. http://doi.org/10.1016/S1474-4422(09)70271-6

Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010b). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology, 9(1), 77–93. http://doi.org/10.1016/S1474-4422(09)70271-6

Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010c). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology, 9(2), 177–89. http://doi.org/10.1016/S1474-4422(09)70272-8

Chaustre, D. M., & Chona, W. S. (2011). Distrofia Muscular de Duchenne. Perspectivas Desde La Rehabilitación. Revista Facultad de Medicina, 19(1), 45–55.

Ciafaloni, E., Fox, D. J., Pandya, S., Westfield, C. P., Puzhankara, S., Romitti, P. a, … Moxley, R. T. (2009). Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). The Journal of Pediatrics, 155(3), 380–5. http://doi.org/10.1016/j.jpeds.2009.02.007

Connolly, A. M., Florence, J. M., Cradock, M. M., Malkus, E. C., Schierbecker, J. R., Siener, C. a, … Eagle, M. (2013). Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscular Disorders : NMD, 23(7), 529–39. http://doi.org/10.1016/j.nmd.2013.04.005

Cowan, D. P. (2012). Guía De Práctica Clínica. Reu-30, (Enfermedad de Paget), 1–18.

Emery, A. E. H. & Emery, M. L. H. (1993). Edward Meryon (1809-1880) and muscular dystrophy. Journal of Medical Genetics, 30(6), 506–511. http://doi.org/10.1136/jmg.30.6.506

En, C., & Emergencia, L. O. S. C. D. E. (n.d.). DIAGNÓSTICO Y MANEJO DE LA DISTROFIA MUSCULAR DUCHENNE , 1–36.

Esterhuizen, A. I., Wilmshurst, J. M., Goliath, R. G., & Greenberg, L. J. (2014). Duchenne muscular dystrophy: High-resolution melting curve analysis as an affordable diagnostic mutation scanning tool in a South African cohort. South African Medical Journal, 104(11), 779. http://doi.org/10.7196/samj.8257

Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013). Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nature Reviews. Genetics, 14(6), 373–8. http://doi.org/10.1038/nrg3460

Flanigan, K. M., Voit, T., Rosales, X. Q., Servais, L., Kraus, J. E., Wardell, C., … Wright, P. (2014). Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial. Neuromuscular Disorders, 24(1), 16–24. http://doi.org/10.1016/j.nmd.2013.09.004

Gatheridge, M. A., Kwon, J. M., Mendell, J. M., Scheuerbrandt, G., Moat, S. J., Eyskens, F., … Griggs, R. C. (2015). Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review. JAMA Neurology, 73(1), 1–7. http://doi.org/10.1001/jamaneurol.2015.3537

Hegde, M. R., Chin, E. L. H., Mulle, J. G., Okou, D. T., Stephen, T., & Zwick, M. E. (2009). NIH Public Access, 29(9), 1091–1099. http://doi.org/10.1002/humu.20831.Microarray-based

Ishikawa, Y., Bach, J. R., & Minami, R. (n.d.). Cardioprotection for Duchenne ’ s muscular dystrophy, (Dcm).

Koenig, M; Monaco, P; Kungel, L. M. (1988). The complete sequence of Dystrophin predicts a Rod-Shaped cytoskeletal protein. Cell, Vol 53.

Kole, R., & Leppert, B. J. (2012). Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Discovery Medicine. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22846203

Li, X., Zhao, L., Zhou, S., Hu, C., Shi, Y., Shi, W., … Wang, Y. (2015). A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China. Orphanet Journal of Rare Diseases, 10(1), 5. http://doi.org/10.1186/s13023-014-0220-7

Lochm, H., Lynn, S., Roy-toole, C., Braun, S., Board, T. G., Meeting, T. O. C., … Nmds, M. (2014). CHARTER FOR THE TREAT-NMD PATIENT DATABASE / REGISTRY, (October 2007).

Lynn, S., Aartsma-Rus, A., Bushby, K., Furlong, P., Goemans, N., De Luca, A., … Straub, V. (2015). Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscular Disorders, 25(1), 96–105. http://doi.org/10.1016/j.nmd.2014.09.003

Mah, J. K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T., & Jette, N. (2014). A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders : NMD, 24(6), 482–91. http://doi.org/10.1016/j.nmd.2014.03.008

Ministerio de Salud y Protección Social Departamento Administrativo de Ciencia Tecnología e Innovación - Colciencias. (2015). Guía De Práctica Clínica Gpc. Guía de práctica clínica para la detección temprana, atención integral, seguimiento y rehabilitación de pacientes con diagnóstico de distrofia muscular. Retrieved from www.cenetec.salud.gob.mx

Moizard, M. P., Billard, C., Toutain, A., Berret, F., Marmin, N., & Moraine, C. (1998). Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy? American Journal of Medical Genetics, 80(1), 32–41. http://doi.org/10.1002/(SICI)1096-8628(19981102)80:1<32::AID-AJMG6>3.0.CO;2-Y

Muntoni, F., Torelli, S., & Ferlini, A. (2003a). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology, 2(12), 731–740. http://doi.org/10.1016/S1474-4422(03)00585-4

Muntoni, F., Torelli, S., & Ferlini, A. (2003b). Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurology, 2(12), 731–740. http://doi.org/10.1016/S1474-4422(03)00585-4

Na, S.-J., Kim, W.-J., Kim, S. M., Lee, K. O., Yoon, B., & Choi, Y.-C. (2013). Clinical, immunohistochemical, Western blot, and genetic analysis in dystrophinopathy. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 20(8), 1099–105. http://doi.org/10.1016/j.jocn.2012.09.021

Nakabayashi, A., Sueoka, K., Tajima, H., Sato, K., Sakamoto, Y., & Katou, S. (2007). Well-devised quantification analysis for duplication mutation of Duchenne muscular dystrophy aimed at preimplantation genetic diagnosis, 233–240. http://doi.org/10.1007/s10815-007-9111-3

Nakamura, H., Kimura, E., Mori-Yoshimura, M., Komaki, H., Matsuda, Y., Goto, K., … Kawai, M. (2013). Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet Journal of Rare Diseases, 8, 60. http://doi.org/10.1186/1750-1172-8-60

Narvaja, E., & Luisa, M. (2012). Implementación de la Prueba del Multiplex PCR para el Gen DMD en Pacientes con sospecha de Distrofia Muscular de Duchenne / Becker y la identificación de una deleción de los exones 48-51 Establishment of the Multiplex PCR test for the DMD gene in patients.

Pane, M., Fanelli, L., Mazzone, E. S., Olivieri, G., D’Amico, A., Messina, S., … Mercuri, E. (2015). Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 25(10), 749–753. http://doi.org/10.1016/j.nmd.2015.07.009

Pane, M., Lombardo, M. E., Alfieri, P., D’Amico, A., Bianco, F., Vasco, G., … Mercuri, E. (2012). Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. The Journal of Pediatrics, 161(4), 705–9.e1. http://doi.org/10.1016/j.jpeds.2012.03.020

Pane, M., Scalise, R., Berardinelli, A., D’Angelo, G., Ricotti, V., Alfieri, P., … Mercuri, E. (2013). Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders : NMD, 23(6), 451–5. http://doi.org/10.1016/j.nmd.2013.02.012

Pillers, D.-A. M. (2014). A new day for Duchenne’s?: The time has come for newborn screening. Molecular Genetics and Metabolism, 113(1-2), 11–3. http://doi.org/10.1016/j.ymgme.2014.06.001

Rangel, V., Martin, A. S., & Peay, H. L. (2012, January). DuchenneConnect Registry Report. PLoS Currents. http://doi.org/10.1371/currents.RRN1309

Rodino-klapac, L. R., & Mendell, J. R. (2013). Update on the Treatment of Duchenne Muscular Dystrophy, 1–7. http://doi.org/10.1007/s11910-012-0332-1

Romitti, P. A., Zhu, Y., Puzhankara, S., James, K. A., Nabukera, S. K., Zamba, G. K., … Bolen, J. (2015). Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics, 135(3), 513–521. http://doi.org/10.1542/peds.2014-2044

S.J. White, et al. (2006). Duplications in the DMD Gene. Human Mutation, 27(September), 938–945. http://doi.org/10.1002/humu

Santos, R., Gonçalves, A., Oliveira, J., Vieira, E., Vieira, J. P., Evangelista, T., … Bronze-da-Rocha, E. (2014). New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy. Journal of Human Genetics, (February), 1–11. http://doi.org/10.1038/jhg.2014.54

Silva, C. T., Sc, M., Fonseca, D., Restrepo, C. M., Contreras, N. C., & Mateus, H. E. (2004). Colombia Médica Colombia M é dica, 35, 191–198.

Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J., … Flanigan, K. M. (2010). Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders : NMD, 20(8), 499–504. http://doi.org/10.1016/j.nmd.2010.05.010

Spurney, C. F. (2011). Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle & Nerve, 44(1), 8–19. http://doi.org/10.1002/mus.22097

Spurney, C., Shimizu, R., Morgenroth, L. P., Kolski, H., Gordish-Dressman, H., & Clemens, P. R. (2014). Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy. Muscle and Nerve, 50(2), 250–256. http://doi.org/10.1002/mus.24163

Takeshima, Y., Yagi, M., Okizuka, Y., Awano, H., Zhang, Z., Yamauchi, Y., … Matsuo, M. (2010). Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of Human Genetics, 55(6), 379–388. http://doi.org/10.1038/jhg.2010.69

van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003). Advances in Duchenne muscular dystrophy gene therapy. Nature Reviews. Genetics, 4(10), 774–783. http://doi.org/10.1038/nrg1180

Wilton, S. D., Fletcher, S., & Flanigan, K. M. (2014). Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? Neuromuscular Disorders, 24(6), 463–466. http://doi.org/10.1016/j.nmd.2014.03.007

TMGH

Palavras-Chave #Genética evolutiva #Origen del hombre #Genética humana #616.042 #Genética Médica #Duchenne muscular dystrophy #Becker muscular dystrophy #Dystrophinopathies
Tipo

info:eu-repo/semantics/masterThesis

info:eu-repo/semantics/acceptedVersion